


Tfw

Docket No. 2609/68518-A/JPW/GJG/NDP



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants : Sharon Cohen-Vered, et al.  
Serial No. : 10/758,572  
Filed : January 14, 2004  
For : PARENTERAL FORMULATIONS OF A PEPTIDE FOR THE  
TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS

1185 Avenue of the Americas  
New York, New York 10036  
October 12, 2004

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

In accordance with their duty of disclosure under 37 C.F.R. §1.56, applicants would like to direct the Examiner's attention to the following documents which are listed on Form PTO-1449 (**Exhibit A**) and are also listed below. A copy of the references listed below as items 1-5 are attached hereto as **Exhibit 1-5**.

This Information Disclosure Statement is being submitted pursuant to 37 C.F.R. §1.97(b)(3) before the mailing of a first Office Action on the merits. Thus, this Information Disclosure Statement should be entered and considered.

1. PCT International Application Publication No. WO 99/31066 published June 24, 1999 (**Exhibit 1**);

Applicants: Sharon Cohen-Vered et al.  
Serial No.: 10/758,572  
Filed : January 14, 2004  
Page 2

2. Brosch N. et al. (2000) A Peptide Based on the Sequence of the CDR3 of a Murine Anti-DNA mAb is a Better Modulator of Experimental SLE than its Single Amino Acid-Substituted Analogs. Cellular Immunology, 205:52-61 (**Exhibit 2**);
3. Brosch N. et al. (2000) Characterization and Role in Experimental Systemic Lupus Erythematosus of T-cell Lines Specific to Peptides Based on Complementarity-Determining Region-1 and Complementarity-Determining Region-3 of a Pathogenic Anti-DNA Monoclonal Antibody. Immunology 99:257-264 (**Exhibit 3**);
4. Naparstek, Y. et al. (1989) Sequential Anti-Idiotypes Define Reciprocal Idiotopes on the Same Anti-DNA Antibody. Clinical Immunology and Immunopathology, 50:S106-S116 (**Exhibit 4**); and
5. Tsokos G.C. et al. (1999) Immune Cell Signaling Defects in Lupus: Activation, Anergy and Death. Immunology Today (**Exhibit 5**);

Applicants request that the Examiner review the references and make them of record in the subject application.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorney invites the Examiner to telephone him at the number provided below.

Applicants: Sharon Cohen-Vered et al.


Serial No.: 10/758,572

Filed : January 14, 2004

Page 3

No fee is deemed necessary in connection with the filing of this Information Disclosure Statement. However, if any fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

Respectfully submitted,




I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

 10/12/04

John P. White  
Reg. No. 28,678  
Gary J. Gershik  
Reg. No. 39,992

John P. White  
Registration No. 28,678  
Gary J. Gershik  
Registration No. 39,992  
Attorneys for Applicants  
Cooper & Dunham LLP  
1185 Avenue of the Americas  
New York, New York 10036  
(212) 278-0400



Form PTO-1449

**U.S. Department of Commerce  
Patent and Trademark Office**

Atty. Docket No.

68518-A/JPW/GJG/NDP

Serial No.

10/758,572

Applicants: Sharon Cohen-Vered et al.

Filing Date

January 14, 2004

Group

**INFORMATION DISCLOSURE CITATION**  
(Use several sheets if necessary)

**U.S. PATENT DOCUMENTS**

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

**FOREIGN PATENT DOCUMENTS**

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
	WO 9 9 3 1 0 6 6	6/24/99	PCT;				

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

	Brosch N. et al. (2000) A Peptide Based on the Sequence of the CDR3 of a Murine Anti-DNA mAb is a Better Modulator of Experimental SLE than its Single Amino Acid-Substituted Analogs. <u>Cellular Immunology</u> , 205:52-61;
	Brosch N. et al. (2000) Characterization and Role in Experimental Systemic Lupus Erythematosus of T-cell Lines Specific to Peptides Based on Complementarity-Determining Region-1 and Complementarity-Determining Region-3 of a Pathogenic Anti-DNA Monoclonal Antibody. <u>Immunology</u> 99:257-264;
	Naparstek, Y. et al. (1989) Sequential Anti-Idiotypes Define Reciprocal Idiotopes on the Same Anti-DNA Antibody. <u>Clinical Immunology and Immunopathology</u> , 50:S106-S116; and
	Tsokos G.C. et al. (1999) Immune Cell Signaling Defects in Lupus: Activation, Anergy and Death. <u>Immunology Today</u> .

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicants: Sharon Cohen-Vered, et al.  
Serial No.: 10/758,572  
Filed: January 14, 2004  
**Exhibit A**